Chloral hydrate oral (50 mg/kg) vs dexmedetomidine intranasal (3 μg/kg)
- Chloral hydrate as a sedating agent for neurodiagnostic procedures in children 2021 · Cochrane Headline outcomes onlyno estimate extracted1 study · 194 participantsModerate
Chloral hydrate oral (50 mg/kg) leads to lower number of children with clinical adverse event: bradycardia compared with dexmedetomidine intranasal (3 μg/kg) (high certainty).
Chloral hydrate oral (50 mg/kg) showed no clear difference in number of children with clinical adverse event: unsteadiness within… compared with dexmedetomidine intranasal (3 μg/kg) (low certainty).
Chloral hydrate oral (50 mg/kg) probably leads to higher number of children with clinical adverse event: crying during… compared with dexmedetomidine intranasal (3 μg/kg) (moderate certainty).
Chloral hydrate oral (50 mg/kg) showed no clear difference in number of children with clinical adverse event: vomiting compared with dexmedetomidine intranasal (3 μg/kg) (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Chloral hydrate oral (50 mg/kg or 100 mg/kg) showed no clear difference in proportion of children who had sedation failure or inadequate level… compared with dexmedetomidine oral (2 µg/kg or 3 µg/kg) (moderate certainty).
Chloral hydrate oral (50 mg/kg or 100 mg/kg) may leads to higher number of children with clinical adverse events (any) compared with dexmedetomidine oral (2 µg/kg or 3 µg/kg) (low certainty).